Anti-tumour activity of bisphosphonates in human myeloma cells

Leukemia and Lymphoma

Volumn 32, Issue 1-2, 1998, Pages 129-138

  Shipman, Claire M ^a,c   Rogers, Michael J ^a   Apperley, Jane F ^b   Russell, R Graham G ^a,c   Croucher, Peter I ^a,c,d  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; Bisphosphonates; Bone disease; Multiple myeloma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE ATROPHY; BONE DISEASE; BONE MARROW; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PLASMA CELL; PRIORITY JOURNAL; REVIEW;

EID: 0032450839     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059253     Document Type: Review

References (55)

1. Lahtinen, R., Laakso, M., Palva, I., Virkkunen, P. and Elomaa, I. (1992) Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet, 340, 1049-1052.
2. Bataille, R., Chappard, D. and Basle, M. (1995) Excessive bone resorption in human plasmacytomas: Direct induction by tumour cells in vivo. British Journal of Haematology, 90, 721-724.
3. Taube, T., Beneton, M.N.C., McCloskey, E.V., Rogers, S., Greaves, M. and Kanis, J.A. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. European Journal of Haematology, 49, 192-198.
4. Valentin-Opran, A., Charbon, S., Meunier, P.J., Edouard, C.M. and Arlot, M.E. (1982) Quantitative histology of myeloma-induced bone changes. British Journal of Haematology, 52, 601-610.
5. Rossi, J.F., Chappard, D., Marcelli, C., Laplante, J.; Commes, T., Baldet, P., Janbon, C., Jourdan, J., Alexandre, C. and Bataille, R. (1990) Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. British Journal of Haematology, 76, 469-475.
6. Chappard, D., Rossi, J., Bataille, R. and Alexandre, C. (1991) Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma. Calcified Tissue International, 48, 13-17.
7. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J. and Alexandre, C. (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. Journal of Clinical Investigation, 88, 62-66.
8. Mundy, G.R., Raisz, L.G., Cooper, R.A., Schechter, G.P. and Salmon, S. (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England Journal of Medicine, 291, 1041-1046.
9. Mundy, G.R., Luben, R.A., Raisz, L.G., Oppenheim, J.J. and Buell, D.N. (1974) Bone-resorbing activity in supematants from lymphoid cell lines. New England Journal of Medicine, 290, 867-871.
10. Cozzolini, F., Torcia, M., Aldinucci, D., Rubartelli, A., Milani, A., Shaw, A., Landsorp, P. and Di Guglielmo, R. (1989) Production of interleukin-1 by bone marrow myeloma cells. Blood, 74, 380-387.
11. Garrett, I.R., Durie, B.G.M., Newin, G.E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini, D.R. and Mundy, G.R. (1987) Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. New England Journal of medicine, 317, 526-532.
12. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. and Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2\IL-6 for human multiple myelomas. Nature, 32, 83-85.
13. Sati, H.I.A., Greaves, M., Apperley, J.F., Russell, R.G.G. and Croucher, P.I. (1997) Expression of IL-1β and TNFα mRNA by neoplastic plasma cells, detected by dual colour fluorescence in situ hybridisation. Bone, 20, P174 (abstr.).
14. Dallas, S.L., Garret, I.R., Bonewald, L.F., Gilles, J., Boyce, B.F., Radl, J. and Mundy, G.R. (1994) Evidence for a vicious cycle between myeloma growth in bone and osteoclastic bone resorption. Blood, 84, 176a, (abstr.).
15. Barille, S., Collette, M., Bataille, R. and Amiot, M. (1995) Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but down regulate osteocalcin. Blood, 86, 685-691.
16. Garrett, I.R., Dallas, S.L., Bonewald, L.F., Boyce, B.F., Dallas, M., Radl, J. and Mundy, G.R. Evidence for bidirectional interactions between osteoclasts and myeloma cells. Journal of Bone and Mineral Research, 10, S195 (abstr.).
17. Fleisch, H. (1991) Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs, 42, 919-944.
18. Hughes, D.E., Wright, K.R., Uy, H.L., Sasaki, A., Yoneda, T., Roodman, G.D., Mundy, G.R. and Boyce, B.F. (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research, 10, 1478-1487.
19. Frith, J.C., Mönkönnen, J. Russell, R.G.G., Blackburn, G.M. and Rogers, M.J. (1997) Clodronale and liposome-encapsulated clodronate can be metabolised to a toxic ATP analogue, adenosine 5′-(6,β,γ-dichloromethylene)triphosphate by mammalian cells in vitro. Journal of Bone and Mineral Research, 12, 1358-1367.
20. Luckman, S.P., Hughes, D.E., Coxon, F.P., Russell, R.G.G. and Rogers, M.J. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research, 13, 581-589.
21. Rodan, G.A. and Fleisch, H.A. (1996) Bisphosphonates: Mechanisms of action. Journal of Clinical Investigation, 97, 2692-2696.
22. Rogers, M.J. and Russell, R.G.G. (1996) Mechanisms of action of bisphosphonates as inhibitors of bone resorption. The molecular biology of Paget's disease (edited by P.T. Sharpe), p. 147. R.G. Landes Co, Austin, Texas.
23. Hughes, D.E., MacDonald, B.R., Russell, R.G.G. and Gowen, M. (1989) Inhibition of osteoclast-like cell function by bisphosphonates in long-term cultures of human bone marrow. Journal of Clinical Investigation, 83, 1930-1935.
24. Boonekamp, P., van der Wee-Pals, L.M., van Wijk-van Lennep, M.M.L., Thesing, C.W. and Bijvoet, O.L. (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone and Mineral, 1, 27-39.
25. Sahni, M., Guenther, H.L., Fleisch, H., Collin, P. and Martin, T.J. (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. Journal of Clinical Investigation, 91, 2004-2011.
26. Nishikawa, M., Akatsu, T., Katayama, Y., Yasutomo, Y., Kada, S., Kugai, N., Yamamoto, M. and Nagata, N. (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone, 18, 9-14.
27. Mönkkönen, J., Taskinen, M., Auriola, S.O.K. and Urtti, A. (1994) Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. Journal of Drug Targeting, 2, 299-308.
28. [281 Cecchini, M.G., Felix, R., Fleisch, H. and Cooper, P.H. (1987) Effects of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research, 2, 135-142.
29. Rogers, M.J., Watts, D.J., Russell, R.G.G., Ji, X., Xiong, X., Blackburn, G.M., Bayless, A.V. and Ebetino, F.H. (1994) Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. Journal of Bone and Mineral Research, 9, 1029-1039.
30. Fast, D.K., Felix, R., Dowse, C., Neuman, W.F. and Fleisch, H. (1978) The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochemical Journal. 172, 97-107.
31. 2MDP) on rat macrophage-mediated bone resorption in vitro. Journal of Clinical Investigation, 70, 927-932.
32. Van der Pluijm, G., Vloedgraven, H., Van Beek, E., van der Wee-Pals, L., Löwik, C. and Papapoulos, S. (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Journal of Clinical Investigation, 98, 698-705.
33. Rogers, M.J., Chilton, K.M., Coxon, F.P., Lawry, J., Smith, M.O., Suri, S. and Russell, R.G.G. (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. Journal of Bone and Mineral Research, 11, 1482-1491.
34. Delmas, P.D.and Meunier, P.J. (1997) The management of Paget's disease of bone. New England Journal of Medicine, 336, 558-566.
35. Belch, A.R., Bergsagel, D.E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D. and Zee, B. (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. Journal of Clinical Oncology, 9, 1397-1402.
36. Daragon, A., Humez, C., Michot, C., LeLoet, X., Grosbois, B., Pouyol, F., Euller-Ziegler, L., Azais, I., Bernard, J.F. and Monconduit, M. (1993) Treatment of multiple myeloma with etidronate: Results of a multicentre double-blind study. European Journal of Medicine, 2, 449-452.
37. McCloskey, E.V., MacLennan, I.C.M., Drayson, M.T., Chapman, C., Dunn, J. and Kanis, J.A. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology, 100, 317-325.
38. Berenson, J., Lichtenstein, A., Porter, L., Dimopoulos, M., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, J., Reitsma, D., Heffeman, M., Seaman, J. and Knight, R. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488-193.
39. Brincker, H., Westin, J., Abilgaard, N., Gimsing, P., Turesson, I., Hedenus, M., Ford, J. and Kandra, A. (1998) Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. British Journal of Haematology, 101, 280-286.
40. Roux, C., Ravaud, P., Cohen-Solal, M., de Vernejoul, M.C., Guillemant, S., Cherruau, B., Delmas, P., Dougados, M. and Amor, B. (1994) Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone, 15, 41-49.
41. Riccardi, A., Ucci, G., Brugnatelli, S., Mora, O., Merlini, G., Piva, N., De Paoli, A., Barbarano, L., Di Stasi, M., Alberio, F., Nicoletti, G., Moransi, S., Rinaldi, E., Piccini, L. and Ascari, E. (1994) A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. International Journal of Oncology, 5, 833-839.
42. McCloskey, E.V., MacLennan, I.C.M., Drayson, M., Chapman, C., Dunn, J. and Kanis, J.A. (1996) Effect of clodronate on morbidity and mortality in myelomatosis. Annals of Oncology, 7, 4120 (abstr.).
43. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs M., Blacklock, H., Bell, R., Simeone, J.F., Reitsma, D.J., Heffeman, M., Seaman, J. and Knight, R.D. (1998) Long-term pamidronate treatment of avanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology, 16, 593-602.
44. Geddes, A.D., D'Souza, S.M., Ebetino, F.H. and Ibbotson, K.J. (1994) Bisphosphonates; structure-activity relationships and therapeutic implications. Bone and Mineral Research, 8, 265-306.
45. Shipman, C.M., Rogers, M.J., Apperley, J.F., Russell, R.G.G. and Croucher, P.I. (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. British Journal of Haematology, 98, 665-672.
46. Wyllie, A., Kerr, J.F.R. and Currie, A.R. (1980) Cell Death: The significance of Apoptosis. International Review of Cytology, 68, 251-306.
47. Gerschenson, L.E. and Rotello, R.J. (1992) Apoptosis: A different type of cell death. FASEB Journal, 6, 2540-2455.
48. Kerr, J.F.R., Winterford, C.M., Harmon, B.V. (1994) Apoptosis: Its significance in cancer and cancer therapy. Cancer, 73, 2013-2026.
49. Green, J.R., Müller, K. and Jaeggi, K.A. (1994) Preclinical pharmacology of CGP 42′466, a new, potent heterocyclic bisphosphonate compound. Journal of Bone and Mineral Research, 9, 745-751.
50. Aparichio, A., Gardner, A., Tu, Y., Berenson, J. and Lichtenstein, A. (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia, 12, 220-229.
51. Wingen, F., Pool, B.L., Klein, P., Klenner, T. and Schmähl, D. (1988) Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat; benefit of combining bisphosphonates with cytostatic agents. Investigational New Drugs, 6, 155-167.
52. Wingen, F., Klenner, T. and Schmähl, D. (1989) Are all anticancer effects of pamidronate (APD) and related compounds bone-mediated?. The Management of Bone Metastases and Hypercalcaemia by Osteoclast Inhibition, Fifth European Conference on Clinical Oncology, p.111. Hogrefe and Huber, Bern.
53. Radl, J., Croese, J.W., Zurcher, C., Van den Endenvieveen, M.H.M., Brondijk, R.J., Kazil, M. Haajman, J.J., Reitsma, P.H. and Bijvoet, O.L.M. (1985) Influence of treatment with APD-bisphosphonate in the mouse 5T2 multiple myeloma. Cancer, 55, 1030-1040.
54. Sasaki, A., Boyce, B.F., Story, B., Wright, K.R., Chapman, M., Boyce, R., Mundy, G.R. and Yoneda, T. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research, 55, 3551-3557.
55. Berenson, J.R. (1997) Bisphosphonates in multiple myeloma. Cancer, 80, 1661-1667.